Rani Therapeutics has developed the RaniPill platform, which enables the oral delivery of biologics, including proteins and antibodies, with bioavailability comparable to subcutaneous injections. This technology addresses the challenges of painful and inconvenient injections for patients requiring chronic biologic treatments, improving compliance and quality of life.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients with chronic conditions require biologic drugs that are currently administered via injection. These injections can be painful and inconvenient, leading to reduced patient compliance and a lower quality of life.
Solution
Rani Therapeutics has developed the RaniPill platform, a novel approach for the oral delivery of biologics, including proteins, peptides, and antibodies. The RaniPill capsule offers a non-invasive alternative to subcutaneous injections, potentially improving patient adherence and overall treatment outcomes. Preclinical and clinical studies have demonstrated high reliability, safety, and tolerability in humans, with bioavailability comparable to or better than subcutaneous injections. This technology aims to transform the delivery of biologic drugs across a wide range of therapeutic areas.
Target Audience
The primary target audience includes patients with chronic conditions requiring biologic drugs, as well as pharmaceutical companies seeking to improve drug delivery methods and patient outcomes.
Features
- Oral delivery of biologics, eliminating the need for injections
- RaniPill capsule designed for reliable and targeted drug release
- Demonstrated safety and tolerability in human clinical trials
- Bioavailability comparable to or better than subcutaneous injections
- Potential for improved patient compliance and quality of life
- Applicable to a wide range of therapeutic areas and biologic payloads